摘要 目的探讨解聚素-金属蛋白酶17(ADAM17)与表皮生长因子受体(EGFR)在脑胶质瘤组织中的表达及临床意义。方法选择2014年2月至2016年8月手术切除68例新鲜脑胶质瘤标本,其中高级别胶质瘤42例,低级别胶质瘤26...展开更多 Objective To investigate the expressions of adisintegrin and metalloproteinase17(ADAM17)and ...
Osimertinib and chemotherapy provide similar OS benefits in patients with T790M-positive tumors.#Different prognostic meaning of tumor resistant gene detected from tumor or blood in patients with EGFR-mutant lung cancer#The study demonstrates that patients with EGFR-mutant lung can...
Meaning Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with non–small cell lung cancer who previously underwent EGFR-TKI treatment and may offer a new treatment option for patients with TKI resistance. Abstract Importance For pat...
埃万妥珠单抗: 一种EGFR拮抗剂、c-Met抑制剂药物,由Genmab BV (Genmab BV)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: EGFR拮抗剂(表皮生长因子受体erbB1拮抗剂),c-Met抑制剂(肝细胞生长因子受体抑制剂),治疗领域: 肿瘤,呼吸系统疾病,消化系统疾病,在
Department of Medical Oncology, Tianjin Medical University General Hospital, No.154, Anshandao, Heping District, Tianjin, 300052, China Linlin Zhang & Diansheng Zhong Department of Thoracic Oncology, Tianjin Lung Cancer Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Resear...
Curiously, SW756 and CaSki are the cell lines with the highest EGFR phosphorylation levels at basal conditions, meaning that they are hypothetically under EGFR control, and the quantity or time of EGF treatment was not enough to impact RKIP expression. To test this hypothesis, we treated the ...
The importance and meaning of this interaction need to be further analyzed in vivo, given the fact that PPAR is considered a tumor suppressor gene and clinical trials using PPAR-agonists in the treatment of cancer are in course [85]. The activity of EGFR can be modulated by post-...
CtDNA testing may be used to detect mutations that make the tumor sensitive to targeted therapy (sensitizing mutations). However, ctDNA testing is known to sometimes give false-negative results (meaning the mutation is present but not detected by the ctDNA testing). For this reason, the FDA ...
“Completing enrollment in the HARMONi study represents another step towards our goal of bringing to patients a drug that is intended to improve the quality and potential duration of life for those facing serious unmet medical needs,” stated Robert W. Duggan, Chairman & Chief Executive Officer of...
Meaning The findings of this randomized clinical trial suggest that gefitinib plus chemotherapy may be a viable first-line treatment for patients with brain metastases associated with EGFR-mutant NSCLC. Abstract Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal gr...